EASL is committed to furthering research in the field of hepatology to improve the lives of everyone affected by liver disease. The combined efforts of all stakeholders in the public and private sectors, and civil society are essential to halting and reversing liver disease. As such, EASL acknowledges that every voice is valued. EASL embraces freedom of expression during The International Liver Congress(ILC) as an essential principle in the response to progressing liver disease and in promoting full participation during the congress. However, EASL is responsible for maintaining the safety of all attendees and as such, must balance the need of allowing all participants to be heard while ensuring the Congress is not disrupted.
The scientific session is the world premier diabetes meeting, bringing together over 14000 Participants including more than 11000 physicians, clinicians, nurses, dietitians, CDE A and researchers, Join over 145 companies representing 700 booths.